Landos Biopharma, Inc. (LABP): history, ownership, mission, how it works & makes money

A Brief History of Landos Biopharma, Inc. (LABP)

Formation and Early Years

Landos Biopharma, Inc. was founded in 2017 by Dr. A. Craig Kallman and his team, focusing on developing innovative therapies for autoimmune diseases. The company's primary goal is to provide new treatment options targeting pathways that have been overlooked by traditional therapies.

Corporate Developments

In May 2019, Landos Biopharma announced its merger with Rising Biosciences, Inc., which allowed the company to gain access to additional resources and an expanded pipeline. This merger was significant as it helped establish a stronger platform for drug development.

Clinical Trials and Pipeline Progression

Landos Biopharma has been focused on advancing its lead product candidate, LB1001, a novel small molecule therapeutic for patients with inflammatory bowel diseases (IBD). As of September 2022, the company entered Phase 2 clinical trials, aiming to evaluate LB1001's efficacy and safety.

Financial Performance

For the fiscal year ending December 31, 2022, Landos Biopharma reported revenues of $1.2 million, primarily from grant funding and collaborations. The company's operating expenses for the same period totaled $12 million, attributed to research and development costs.

Stock Market Activity

Landos Biopharma became publicly traded on the NASDAQ under the ticker symbol LABP following a merger with Union Acquisition Corp. on November 22, 2021. The closing share price on November 24, 2021, was approximately $9.50. As of March 2023, LABP shares traded at around $2.50.

Collaborations and Partnerships

The company has established numerous collaborations to enhance its research capabilities. In early 2023, Landos partnered with TopiX Pharmaceuticals to co-develop LB1001, facilitating shared resources and expertise in drug development.

Future Outlook

Landos Biopharma anticipates significant milestones in its pipeline over the coming years, with potential regulatory submissions planned for LB1001 in late 2024 based on successful Phase 2 results. Investment in technology and expansion of clinical trials are central to the company’s strategic direction.

A Who Owns Landos Biopharma, Inc. (LABP)

Overview of Landos Biopharma, Inc.

Landos Biopharma, Inc. (LABP) is a clinical-stage biopharmaceutical company focused on developing therapies for patients with autoimmune diseases. The company was established in 2017 and is publicly traded on the NASDAQ under the ticker symbol LABP.

Major Shareholders

The ownership structure of Landos Biopharma can be broken down as follows:

Institutional Investors

Key institutional investors in Landos Biopharma include:

Insider Ownership

Insider ownership comprises key executives and board members:

Recent Stock Performance

As of October 2023, Landos Biopharma's stock price is approximately $7.50.

The market capitalization of Landos Biopharma, Inc. is around $75 million.

The stock's performance over the past six months shows a volatility rate of approximately 35%.

Capital Structure

The capital structure of Landos Biopharma includes the following components:

Conclusion of Ownership Data

Landos Biopharma's ownership structure illustrates a significant presence of institutional investors, alongside a modest amount held by insiders and retail investors. This distribution is indicative of a supportive base for the company's financial and operational endeavors.

Landos Biopharma, Inc. (LABP) Mission Statement

Core Purpose

Landos Biopharma, Inc. aims to transform the lives of patients with autoimmune diseases by delivering innovative therapies that target unmet medical needs. The company prioritizes the development of advanced therapeutics that enhance patient outcomes through precision medicine.

Commitment to Innovation

The mission statement emphasizes a commitment to cutting-edge research and development. Landos Biopharma invests significantly in its R&D pipeline, with a reported R&D expenditure of approximately $21.1 million in 2022. This investment underpins the development of novel treatments for conditions such as inflammatory bowel disease (IBD).

Patient-Centric Approach

Landos recognizes the importance of a patient-centric approach. They focus on aligning their product development with the needs and experiences of patients. The mission statement reflects their dedication to listen to patients and healthcare professionals to ensure that their therapies address real-world challenges.

Strategic Partnerships

Partnerships play a crucial role in Landos' mission. The company collaborates with various research institutions and pharmaceutical companies. One such collaboration is with the University of North Carolina, aimed at furthering the understanding of IBD.

Financial Overview

Future Aspirations

Landos Biopharma’s mission extends to proactively expanding its market presence. The company targets a broader geolocation for its therapies, focusing on markets with high unmet needs. Their goal includes gaining FDA approval for multiple candidates within the next five years.

Social Responsibility

In addition to pursuing financial success, Landos is committed to social responsibility, aiming to make a positive impact on communities through healthcare accessibility and educational initiatives.

Conclusion

The mission statement of Landos Biopharma underlines a robust framework targeting innovation, patient engagement, and strategic growth, reflecting its dedication to addressing significant healthcare challenges in autoimmune diseases.

How Landos Biopharma, Inc. (LABP) Works

Company Overview

Landos Biopharma, Inc. (LABP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases. The company aims to meet unmet medical needs in conditions such as inflammatory bowel disease (IBD) and other immunologically driven disorders.

Business Model

The business model of Landos Biopharma revolves around drug development, which includes the discovery, preclinical, and clinical phases. The company seeks to advance its proprietary programs through various stages of development to eventually gain regulatory approval.

Key Pipeline Candidates

Landos Biopharma’s primary product candidates include:

• LBP-919: A novel oral therapeutic agent for ulcerative colitis.
• LBP-671: A candidate for Crohn’s disease therapy.
• additional pipeline candidates targeting other autoimmune diseases.

Financial Overview

As of the latest fiscal reports, Landos Biopharma has the following financials:

Clinical Trials

Landos actively conducts clinical trials to evaluate the safety and efficacy of its drug candidates. The progress in these trials is crucial for the company's pathway to commercialization:

• Phase 1 Trials for LBP-919 have shown promising safety profiles.
• Phase 2 Trials for LBP-671 are ongoing with expected data readouts in 2023.

Partnerships and Collaborations

Collaboration is a vital aspect of Landos Biopharma’s strategy:

• Partnership with major pharmaceutical companies for advancement of clinical programs.
• Collaborations with research institutions for innovative drug discovery processes.

Intellectual Property

Landos Biopharma holds a robust intellectual property portfolio which includes:

• Multiple issued patents related to drug formulations and uses.
• Pending patent applications that secure future products.

Regulatory Environment

Landos Biopharma operates under the regulatory oversight of the FDA and other global regulatory bodies. The status of regulatory submissions is pivotal for the timeline of product availability:

• Pre-IND submissions and discussions for pipeline candidates.
• Ongoing interactions with regulatory agencies to ensure compliance.

Market Potential and Competitive Landscape

The autoimmune disease market presents significant opportunities, with estimates suggesting:

Recent Developments

Recent activities at Landos Biopharma include:

• Appointment of new Executive Team members to enhance strategic direction.
• Announced collaborations with academic institutions to expand research capabilities.
• Completion of Series A funding round raising $30 million for further development.

How Landos Biopharma, Inc. (LABP) Makes Money

Product Development and Commercialization

Landos Biopharma focuses primarily on developing and commercializing therapies for autoimmune diseases. Their lead product candidate, LBP-04, is in clinical trials targeting conditions such as ulcerative colitis and Crohn’s disease. Autoimmune disease treatments represent a lucrative market, with expected revenues in the billions.

Funding and Investment

LABP has raised significant funds through various rounds of financing. As of the latest update in 2023, the company completed a $41 million public offering. Their funding strategy includes:

• Initial public offerings (IPOs)
• Private placements
• Grants for research and development

Partnerships and Collaborations

Strategic partnerships are critical for LABP’s revenue generation. Collaborations with larger pharmaceutical companies may provide upfront payments, milestone payments, and royalties on product sales. Recently, LABP entered into a partnership with a major biopharmaceutical company valued at $30 million in potential milestone payments.

Market Potential of Current Candidates

The market potential for LBP-04 is substantial. For instance, the market for inflammatory bowel disease therapeutics was valued at approximately $17 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 8% through 2027.

Regulatory Milestones and Approvals

Securing FDA approvals for drug candidates can lead to lucrative market entry. Each successful regulatory milestone can lead to significant financial incentives. LABP has planned submissions to the FDA that could include $15 million in milestone revenue upon approval.

Revenue from Licensing Agreements

LABP could also generate income via licensing agreements with other biotech firms. Licensing fees and royalties from successful product sales can contribute substantially to overall revenue.

Long-term Growth Projections

Market analysts predict that the demand for autoimmune disease treatments will continue to rise, projecting potential growth in LABP revenues to exceed $200 million annually by 2030 if current product candidates successfully enter the market.